Oxazolidinone (ABSSSI / MRSA — 6-Day Course) Pregnancy: May cause fetal harm based on animal reproduction studies; available human data are insufficient to evaluate drug-associated risk. Advise pregnant women of the potential risk to the fetus.

Tedizolid

Brand names: Sivextro

Tedizolid is an oxazolidinone antibacterial licensed for acute bacterial skin and skin-structure infections caused by susceptible Gram-positive organisms, including MRSA.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 200 mg

Route: Oral or intravenous (IV infusion over 1 hour)

Frequency: Once daily for 6 days

Acute bacterial skin and skin structure infections (ABSSSI) in adults: 200 mg once daily for 6 days, orally (tablet, with or without food) or as an IV infusion over 1 hour. No dose adjustment is necessary when switching from IV to oral. US labelling (SIVEXTRO) — cross-check against UK SPC. Paediatric dosing is weight-band based (IV from at least 26 weeks gestational age and at least 1 kg; oral tablets only for patients weighing 35 kg or more, at 200 mg once daily) — verify against a children's formulary; do not give tablets to children under 35 kg.

Dose auto-extracted from US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

None stated in the source labelling

Side effects

Nausea
Headache
Diarrhoea
Infusion- or injection-related reactions; vomiting
Dizziness

Interactions

Breast Cancer Resistance Protein (BCRP) substrates (e.g. methotrexate, topotecan, rosuvastatin): oral tedizolid can increase their plasma concentrations — monitor or interrupt the substrate
Serotonergic agents (SSRIs, SNRIs, tricyclics, triptans, opioids such as meperidine): potential for serotonin syndrome

Clinical monograph

How it works

It binds the 50S ribosomal subunit and inhibits formation of the functional initiation complex, thereby preventing bacterial protein synthesis.

Prescribing in practice

It is a weak, reversible monoamine oxidase inhibitor, so review concurrent serotonergic and adrenergic drugs for the potential risk of serotonin syndrome and hypertensive effects.
Safety and efficacy in neutropenic patients have not been established, so consider alternatives where neutropenia is a concern.
It is active against Gram-positive bacteria only and should not be relied upon for Gram-negative or mixed infections.

Monitoring

Monitor the full blood count, particularly with courses extending beyond the licensed duration, and observe clinical response.

Counselling the patient

Tell your team if you take antidepressants or other serotonergic medicines.
It can be taken with or without food and may be given by mouth or by infusion.
Report new visual symptoms or unusual tiredness.

Evidence & guidelines

Licensing was supported by the ESTABLISH phase 3 trials demonstrating non-inferiority to linezolid in acute bacterial skin and skin-structure infections.

Reference: Prokocimer et al. JAMA 2013 (ESTABLISH-1); Moran et al. NEJM 2014 (ESTABLISH-2); MHRA SPC Sivextro; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways